Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Nguyen

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
Plos One|December 31, 2013
Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progressionIngrid Marcq, Rémy Nyga, Flora Cartier, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 2, 2025
Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohortXixi Ye-Tran, Mohamed Bouattour, Brice Fresneau, et al.
The Lancet. Gastroenterology & Hepatology|July 10, 2018
Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysisEric Nguyen-Khac, Maja Thiele, Cosmin Voican, et al.
JAMA|May 9, 2023
Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical TrialAlexandre Louvet, Julien Labreuche, Thong Dao, et al.
Kidney International|May 9, 2018
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effectiveLaurent Alric, Isabelle Ollivier-Hourmand, Emilie Bérard, et al.
Journal of Hepatology|November 24, 2022
Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohortAlexandre Louvet, Valérie Bourcier, Isabelle Archambeaud, et al.
Hepatology (Baltimore, Md.)|June 5, 2013
Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitisOriol Morales-Ibanez, Marlene Domínguez, Sung H Ki, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
Liver Cancer|December 15, 2025
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional StudyFrançois Villeret, Mohamed Bouattour, Jean-Frédéric Blanc, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
Plos One|December 31, 2013
Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progressionIngrid Marcq, Rémy Nyga, Flora Cartier, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 2, 2025
Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohortXixi Ye-Tran, Mohamed Bouattour, Brice Fresneau, et al.
The Lancet. Gastroenterology & Hepatology|July 10, 2018
Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysisEric Nguyen-Khac, Maja Thiele, Cosmin Voican, et al.
JAMA|May 9, 2023
Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical TrialAlexandre Louvet, Julien Labreuche, Thong Dao, et al.
Kidney International|May 9, 2018
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effectiveLaurent Alric, Isabelle Ollivier-Hourmand, Emilie Bérard, et al.
Journal of Hepatology|November 24, 2022
Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohortAlexandre Louvet, Valérie Bourcier, Isabelle Archambeaud, et al.
Hepatology (Baltimore, Md.)|June 5, 2013
Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitisOriol Morales-Ibanez, Marlene Domínguez, Sung H Ki, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
Liver Cancer|December 15, 2025
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional StudyFrançois Villeret, Mohamed Bouattour, Jean-Frédéric Blanc, et al.
Pageof 15